Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Literature Search and Selection of Studies
2.2. Eligibility Criteria
2.3. Data Extraction and Quality Assessment
2.4. Statistical Analyses
3. Results
3.1. Literature Search
3.2. Study Characteristics
3.3. Choline and Overall Survival
3.4. Choline and Progression-Free Survival
3.5. The Prognostic Value of Other Metabolites Measured Using 1H-MRS
3.6. Publication Bias
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Ostrom, Q.T.; Price, M.; Neff, C.; Cioffi, G.; Waite, K.A.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro. Oncol. 2022, 24 (Suppl. S5), v1–v95. [Google Scholar] [CrossRef] [PubMed]
- Miller, K.D.; Ostrom, Q.T.; Kruchko, C.; Patil, N.; Tihan, T.; Cioffi, G.; Fuchs, H.E.; Waite, K.A.; Jemal, A.; Siegel, R.L.; et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J. Clin. 2021, 71, 381–406. [Google Scholar] [CrossRef] [PubMed]
- Tiwari, V.; Daoud, E.V.; Hatanpaa, K.J.; Gao, A.; Zhang, S.; An, Z.; Ganji, S.K.; Raisanen, J.M.; Lewis, C.M.; Askari, P.; et al. Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. Neuro. Oncol. 2020, 22, 1018–1029. [Google Scholar] [CrossRef]
- Wang, Q.; Zhang, H.; Zhang, J.; Wu, C.; Zhu, W.; Li, F.; Chen, X.; Xu, B. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis. Eur. Radiol. 2016, 26, 2670–2684. [Google Scholar] [CrossRef] [PubMed]
- Nelson, S.J.; Kadambi, A.K.; Park, I.; Li, Y.; Crane, J.; Olson, M.; Molinaro, A.; Roy, R.; Butowski, N.; Cha, S.; et al. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Neuro. Oncol. 2017, 19, 430–439. [Google Scholar] [CrossRef] [Green Version]
- Ježek, P. 2-hydroxyglutarate in cancer cells. Antioxid. Redox Signal. 2020, 33, 903–926. [Google Scholar] [CrossRef] [Green Version]
- Warren, K.E.; Frank, J.A.; Black, J.L.; Hill, R.S.; Duyn, J.H.; Aikin, A.A.; Lewis, B.K.; Adamson, P.C.; Balis, F.M. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J. Clin. Oncol. 2000, 18, 1020–1026. [Google Scholar] [CrossRef]
- Tarnawski, R.; Sokol, M.; Pieniazek, P.; Maciejewski, B.; Walecki, J.; Miszczyk, L.; Krupska, T. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 1271–1276. [Google Scholar] [CrossRef]
- Kuznetsov, Y.E.; Caramanos, Z.; Antel, S.B.; Preul, M.C.; Leblanc, R.; Villemure, J.G.; Pokrupa, R.; Olivier, A.; Sadikot, A.; Arnold, D.L. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003, 53, 565–574; discussion 574–576. [Google Scholar] [CrossRef]
- Oh, J.; Henry, R.G.; Pirzkall, A.; Lu, Y.; Li, X.; Catalaa, I.; Chang, S.; Dillon, W.P.; Nelson, S.J. Survival analysis in patients with glioblastoma multiforme: Predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J. Magn. Reson. Imaging 2004, 19, 546–554. [Google Scholar] [CrossRef]
- Hattingen, E.; Delic, O.; Franz, K.; Pilatus, U.; Raab, P.; Lanfermann, H.; Gerlach, R. (1)H MRSI and progression-free survival in patients with WHO grades II and III gliomas. Neurol. Res. 2010, 32, 593–602. [Google Scholar] [CrossRef] [PubMed]
- Hipp, S.J.; Steffen-Smith, E.; Hammoud, D.; Shih, J.H.; Bent, R.; Warren, K.E. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro-Oncology 2011, 13, 904–909. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamasaki, F.; Kurisu, K.; Kajiwara, Y.; Watanabe, Y.; Takayasu, T.; Akiyama, Y.; Saito, T.; Hanaya, R.; Sugiyama, K. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neuro-Oncology 2011, 13, 791–801. [Google Scholar] [CrossRef] [PubMed]
- Roldan-Valadez, E.; Rios, C.; Motola-Kuba, D.; Matus-Santos, J.; Villa, A.R.; Moreno-Jimenez, S. Choline-to-N-acetyl aspartate and lipids-lactate-to-creatine ratios together with age assemble a significant Cox’s proportional-hazards regression model for prediction of survival in high-grade gliomas. Br. J. Radiol. 2016, 89, 20150502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Durmo, F.; Rydelius, A.; Cuellar Baena, S.; Askaner, K.; Lätt, J.; Bengzon, J.; Englund, E.; Chenevert, T.L.; Björkman-Burtscher, I.M.; Sundgren, P.C. Multivoxel 1H-MR spectroscopy biometrics for Preoprerative differentiation between brain tumors. Tomography 2018, 4, 172–181. [Google Scholar] [CrossRef] [PubMed]
- Gao, W.; Wang, X.; Li, F.; Shi, W.; Li, H.; Zeng, Q. Cho/Cr ratio at MR spectroscopy as a biomarker for cellular proliferation activity and prognosis in glioma: Correlation with the expression of minichromosome maintenance protein 2. Acta Radiol. 2019, 60, 106–112. [Google Scholar] [CrossRef]
- Cui, Y.; Zeng, W.; Jiang, H.; Ren, X.; Lin, S.; Fan, Y.; Liu, Y.; Zhao, J. Higher Cho/NAA ratio in postoperative peritumoral edema zone is associated with earlier recurrence of glioblastoma. Front Neurol. 2020, 11, 592155. [Google Scholar] [CrossRef]
- Autry, A.W.; Lafontaine, M.; Jalbert, L.; Phillips, E.; Phillips, J.J.; Villanueva-Meyer, J.; Berger, M.S.; Chang, S.M.; Li, Y. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas. J. Neurooncol. 2022, 159, 43–52. [Google Scholar] [CrossRef]
- Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J. Clin. Epidemiol. 2009, 62, e1–e34. [Google Scholar] [CrossRef] [Green Version]
- Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8, 16. [Google Scholar] [CrossRef]
- Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603–605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chaumeil, M.M.; Lupo, J.M.; Ronen, S.M. Magnetic resonance (MR) metabolic imaging in glioma. Brain Pathol. 2015, 25, 769–780. [Google Scholar] [CrossRef] [PubMed]
- Peeling, J.; Sutherland, G. High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn. Reson. Med. 1992, 24, 123–136. [Google Scholar] [CrossRef] [PubMed]
- Pucci, S.; Fasoli, F.; Moretti, M.; Benfante, R.; Di Lascio, S.; Viani, P.; Daga, A.; Gordon, T.J.; McIntosh, M.; Zoli, M.; et al. Choline and nicotine increase glioblastoma cell proliferation by binding and activating α7- and α9- containing nicotinic receptors. Pharmacol. Res. 2021, 163, 105336. [Google Scholar] [CrossRef]
- Kong, Z.; Jiang, C.; Liu, D.; Chen, W.; Ma, W.; Cheng, X.; Wang, Y. Quantitative features from CHO PET distinguish the WHO grades of primary diffuse glioma. Clin. Nucl. Med. 2021, 46, 103–110. [Google Scholar] [CrossRef]
- Kong, Z.; Zhang, Y.; Liu, D.; Liu, P.; Shi, Y.; Wang, Y.; Zhao, D.; Cheng, X.; Wang, Y.; Ma, W. Role of traditional CHO PET parameters in distinguishing IDH, tert and MGMT alterations in primary diffuse gliomas. Ann. Nucl. Med. 2021, 35, 493–503. [Google Scholar] [CrossRef]
- Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; et al. The 2021 WHO Classification of Tumors of the central nervous system: A summary. Neuro. Oncol. 2021, 23, 1231–1251. [Google Scholar] [CrossRef]
- Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739–744. [Google Scholar] [CrossRef] [Green Version]
- Huang, L.E. Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis 2019, 40, 1299–1307. [Google Scholar] [CrossRef]
- Grande, S.; Palma, A.; Ricci-Vitiani, L.; Luciani, A.M.; Buccarelli, M.; Biffoni, M.; Molinari, A.; Calcabrini, A.; D’Amore, E.; Guidoni, L.; et al. Metabolic Heterogeneity Evidenced by MRS among Patient-Derived Glioblastoma Multiforme Stem-Like Cells Accounts for Cell Clustering and Different Responses to Drugs. Stem. Cells Int. 2018, 2018, 3292704. [Google Scholar] [CrossRef]
- Grande, S.; Palma, A.; Luciani, A.M.; Anello, P.; Ricci-Vitiani, L.; Buccarelli, M.; D’Alessandris, Q.G.; Pallini, R.; Guidoni, L.; Viti, V.; et al. Glioblastoma Stem-Like Cells (GSCs) with Mesenchymal Signature: Lipid Profiles of Mobile Lipids Obtained with MRS before and after Radio/Chemical Treatments. Biomolecules 2022, 12, 1051. [Google Scholar] [CrossRef] [PubMed]
Author (Year of Publication) | Country | Study Design | Number of Patients | Glioma Subtype | WHO Grade | Primary or Recurrent | Median Age (Range) | Male/Female Ratio |
---|---|---|---|---|---|---|---|---|
Warren et al. (2000) | USA | Prospective | 27 | Pediatric glioma a | Mix | Recurrent | 14 (5–20) | NA |
Tarnawski et al. (2002) | Poland | Prospective | 51 | Adult glioma b | High grade | Primary | 47 (20–68) | 35:16 |
Kuznetsov et al. (2003) | Canada | Retrospective | 54 | Adult glioma | Low grade | Primary | 45.7 (19–82) | NA |
Oh et al. (2004) | USA | Prospective | 28 | Adult glioma | High grade | Primary | 53.7 (14.6–79.6) | NA |
Hattingen et al. (2010) | Germany | Retrospective | 61 | Adult glioma | Low grade | Primary | 38 (20–66) | 37:24 |
Hipp et al. (2011) | USA | Prospective | 34 | Pediatric glioma | Mix | Primary | 5.5 (1.6–14.6) | 12:22 |
Yamasaki et al. (2011) | Japan | Retrospective | 19 | Pediatric glioma | Mix | Primary | 13.5 (4–36) | 10:9 |
Roldan-Valadez et al. (2016) | Mexico | Retrospective | 28 | Adult glioma | High grade | Primary | 50 (13–85) | 9:19 |
Nelson et al. (2016) | USA | Prospective | 43 | Adult glioma | High grade | Primary | 57 (27–80) | NA |
Durmo et al. (2018) | Sweden | Retrospective | 33 | Adult glioma | Mix | Primary | 57 (27–77) | 11:22 |
Gao et al. (2018) | China | Retrospective | 43 | Adult glioma | Mix | Primary | 47 (8–66) | 28:25 |
Cui et al. (2020) | China | Retrospective | 67 | Adult glioma | High grade | Primary | 47.1 (25.5–58.7) | 41:26 |
Tiwari et al. (2020) | USA | Prospective | 35 | Adult glioma | Mix | Primary | 39 (21–79) | 19:16 |
Autry et al. (2022) | USA | Prospective | 45 | Adult glioma | Low grade | Mix | 34 (19–72) | 33:12 |
Author (Year of Publication) | Magnet Strength (T) | Vendor | MRS Techniques | TE (ms) | Software | Timing of MRS | Adjusted Factors | Parameter | Cutoff |
---|---|---|---|---|---|---|---|---|---|
Warren et al. (2000) | 1.5 | GE | PRESS a | NA | Sun Workstation | Post-treatment | None | Cho/NAA | 4.5 |
Tarnawski et al. (2002) | 2 | Elscint | PRESS | 35 | NA | Pre-surgery | Age | Lac/NAA | 2 |
Kuznetsov et al. (2003) | 1.5 | Philips | PRESS | 272 | AVIS, MNI/H | Pre-surgery | Low NA/Cr voxels | Cho/Cr | NA |
Lac/Cr | NA | ||||||||
Oh et al. (2004) | 1.5 | GE | PRESS | 144 | NA | Post-surgery | Age | Volume of Cho/NAA > 2 | 15.7 |
Hattingen et al. (2010) | 3 | Siemens | PRESS | 30 144 | LCModel | Pre-surgery | None | Cr | 0.93 |
Hipp et al. (2011) | 1.5 | GE | PRESS | 280 | GE Software | Post-surgery | None | Cho/NAA | NA |
Yamasaki et al. (2011) | 3 | GE | PRESS | 30 | GE Software | Pre-surgery | None | Cho/Cr | 2 |
Cho/NAA | 2 | ||||||||
Lactate | Present | ||||||||
Roldan-Valadez et al. (2016) | 3 | GE | PRESS | 26 144 | Func Tool | Pre-surgery | Age | Cho/NAA | NA |
LL/Cr b | NA | ||||||||
Nelson et al. (2016) | 3 | GE | PRESS | 144 | Linux Workstation | Post-surgery | None | Volume of Cho/NAA > 2 | NA |
Durmo et al. (2018) | 3 | Siemens | PRESS | 144 | LCModel | Pre-surgery | None | Ins/Cho | 1.29 |
Gao et al. (2018) | 3 | Siemens | PRESS | 135 | Siemens Platform | Pre-surgery | MCM2 labeling index | Cho/Cr | 2.68 |
Cui et al. (2020) | 3 | Siemens | PRESS | 135 | NA | Post-surgery | Radiotherapy, MGMT methylation | Cho/NAA | 1.31 |
Tiwari et al. (2020) | 3 | Philips | PRESS | 97 | Philips Platform | Pre-surgery | None | 2-HG | 1 |
Glycine | 2.5 | ||||||||
Glycine/2-HG | 2.5 | ||||||||
Autry et al. (2022) | 3 | GE | PRESS | 32 65 | LCModel | Pre-surgery | Tumor volume, tumor enhancement | 2-HG/Cr | 0.905 |
Glu/Cr | 0.945 |
Author (Year of Publication) | Parameter | Cutoff | Overall Survival | Progression Free Survival | ||
---|---|---|---|---|---|---|
Hazard Ratio (HR) | 95% CI a | Hazard Ratio (HR) | 95% CI a | |||
Tarnawski et al. (2002) | Lac/NAA | 2 | 14.00 | 3.74–52.35 | NA | NA |
Kuznetsov et al. (2003) | Lac/Cr | NA | 2.69 | 1.63–4.44 | NA | NA |
Hattingen et al. (2010) | Cr | 0.93 | 1.08 | 1.02–1.15 | NA | NA |
Yamasaki et al. (2011) | Lactate | Present | 3.54 | 1.43–8.78 | 3.58 | 1.45–8.86 |
Roldan-Valadez et al. (2016) | LL/Cr | NA | 0.58 | 0.35–0.99 | NA | NA |
Durmo et al. (2018) | Ins/Cho | 1.29 | 2.56 | 1.29–5.06 | NA | NA |
Tiwari et al. (2020) | 2-HG | 1 | 0.26 | 0.095–0.73 | NA | NA |
Glycine | 2.5 | 6.8 | 1.92–24.07 | NA | NA | |
Glycine/2-HG | 2.5 | 20.00 | 4.48–89.39 | |||
Autry et al. (2022) | 2-HG/Cr | 0.905 | NA | NA | 5.59 | 2.08–12.09 |
Glu/Cr | 0.945 | NA | NA | 32.57 | 2.72–389.94 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shi, Y.; Liu, D.; Kong, Z.; Liu, Q.; Xing, H.; Wang, Y.; Wang, Y.; Ma, W. Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review. Metabolites 2022, 12, 1219. https://doi.org/10.3390/metabo12121219
Shi Y, Liu D, Kong Z, Liu Q, Xing H, Wang Y, Wang Y, Ma W. Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review. Metabolites. 2022; 12(12):1219. https://doi.org/10.3390/metabo12121219
Chicago/Turabian StyleShi, Yixin, Delin Liu, Ziren Kong, Qianshu Liu, Hao Xing, Yuekun Wang, Yu Wang, and Wenbin Ma. 2022. "Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review" Metabolites 12, no. 12: 1219. https://doi.org/10.3390/metabo12121219